Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes

被引：0
|
作者：
List, J. F. [1 ]
Woo, V. [2 ]
Morales, E. [3 ]
Tang, W. [1 ]
Fiedorek, F. T. [1 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Hlth Sci Ctr, Diabet Res & Treatment Ctr, Winnipeg, MB, Canada
[3] Ctr Invest Cardiometab, Aguascalientes, Mexico
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
40
引用
收藏
页码：S22 / S23
页数：2
相关论文
共 50 条
  • [1] Efficacy and safety of dapagliflozin in a dose-ranging monotherapy study of treatment-naive patients with type 2 diabetes
    List, James F.
    Woo, Vincent C.
    Villegas, Enrique Morales
    Tang, Weihua
    Fiedorek, Fred T.
    DIABETES, 2008, 57 : A94 - A94
  • [2] Safety and efficacy of a novel extended release formulation of metformin in patients with type 2 diabetes: A dose-ranging study
    Brazg, R
    Decherney, S
    Proszynski, E
    Holland-O'Rourke, D
    Goyvaerts, H
    Pans, M
    Stein, P
    DIABETES, 2000, 49 : A99 - A99
  • [3] A Dose-Ranging Study of Diacerein in Patients With Type 2 Diabetes
    Brown, Carl O.
    Lu, Weishu
    Lin, Emily
    Chen, Calvin
    DIABETES, 2013, 62 : A272 - A273
  • [4] Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes
    Rosenstock, J.
    Aguilar-Salinas, C.
    Klein, E.
    Nepal, S.
    List, J.
    Chen, R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (10) : 2401 - 2411
  • [5] Efficacy and Safety of Dapagliflozin as Monotherapy for Type 2 Diabetes Mellitus in Japanese Patients
    Kaku, Kohei
    Inoue, Satoshi
    Matsuoka, Osamu
    Kiyosue, Arihiro
    Azuma, Haruna
    Hayashi, Nobuya
    Tokudome, Takuto
    Langkilde, Anna Maria
    Parikh, Shamik
    DIABETES, 2012, 61 : A260 - A260
  • [6] Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes
    Rubin, Cindy J.
    Viraswami-Appanna, Kalyanee
    Fiedorek, Fred T.
    DIABETES & VASCULAR DISEASE RESEARCH, 2009, 6 (03): : 205 - 215
  • [7] Dose-ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus
    Kiyosue, A.
    Hayashi, N.
    Komori, H.
    Leonsson-Zachrisson, M.
    Johnsson, E.
    DIABETES OBESITY & METABOLISM, 2013, 15 (10): : 923 - 930
  • [8] Efficacy and safety of tolterodine in patients with detrusor instability: a dose-ranging study
    Rentzhog, L
    Stanton, SL
    Cardozo, L
    Nelson, E
    Fall, M
    Abrams, P
    BRITISH JOURNAL OF UROLOGY, 1998, 81 (01): : 42 - 48
  • [9] Dose-Ranging Study to Determine the Optimum Dose for Imeglimin, a Novel Treatment for Type 2 Diabetes
    Fouqueray, Pascale
    Bolze, Sebastien
    Pirags, Valdis
    Bailey, Clifford J.
    Schernthaner, Guntram
    Inzucchi, Silvio E.
    Gerich, John E.
    Roden, Michael
    Lebovitz, Harold E.
    DIABETES, 2015, 64 : A301 - A301
  • [10] Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study
    Pettus, Jeremy H.
    D'Alessio, David
    Frias, Juan P.
    Vajda, Eric G.
    Pipkin, James D.
    Rosenstock, Julio
    Williamson, Gretchen
    Zangmeister, Miriam A.
    Zhi, Lin
    Marschke, Keith B.
    DIABETES CARE, 2020, 43 (01) : 161 - 168
12345